PWM
VRTX icon

Proathlete Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Proathlete Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$890 – 323
2025
Q2 		$890 Buy
+2
New +$922 ﹤0.01% 252

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Proathlete Wealth Management's VRTX Position: Q3 2025 in Review

Proathlete Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 2 shares — an estimated $890 sold.

Proathlete Wealth Management first reported a position in VRTX in Q2 2025 and held it in 1 quarter. The position peaked at $890 in Q2 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Proathlete Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Proathlete Wealth Management sold 2 Vertex Pharmaceuticals shares in Q3 2025, an estimated $890.
  • Proathlete Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Proathlete Wealth Management's Vertex Pharmaceuticals position peaked at $890 in Q2 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Proathlete Wealth Management's 13F filing for Q3 2025, filed 7 Oct 2025.